Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y, Kitagawa J, Kasahara S, Yamada T, Sawada M, Kaneda Y, Fukuno K, Takada E, Goto H, Lee S, Fujita K, Morishita T, Hara T, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: fukuno k. Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5. Sci Rep. 2023. PMID: 37925551 Free PMC article.
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Nakamura N, Kasahara S, Kitagawa J, Nakamura H, Sawada M, Fukuno K, Shibata Y, Kaneda Y, Hara T, Kanemura N, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: fukuno k. Exp Hematol Oncol. 2022 Feb 25;11(1):9. doi: 10.1186/s40164-022-00264-3. Exp Hematol Oncol. 2022. PMID: 35216626 Free PMC article.
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Hara T, et al. Among authors: fukuno k. Hematol Oncol. 2018 Oct;36(4):638-644. doi: 10.1002/hon.2524. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882279 Clinical Trial.
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T, Moriwaki H. Goto N, et al. Among authors: fukuno k. Ann Hematol. 2012 May;91(5):705-714. doi: 10.1007/s00277-011-1363-4. Epub 2011 Dec 21. Ann Hematol. 2012. PMID: 22183251
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H, Hara T, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Shimizu M, Takahashi T, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: fukuno k. Leuk Lymphoma. 2012 Feb;53(2):247-53. doi: 10.3109/10428194.2011.606383. Leuk Lymphoma. 2012. PMID: 21827339 Clinical Trial.
36 results